miR-125a增强多西他赛对乳腺癌生长的抑制作用

摘要

Background and purpose: MiR-125a is known to inhibit the proliferation of breast carcinoma cells by knockdown Her-2/3 gene expressions, hence, miR-125a may be a novel therapy target. This study was to investigate the effect of miR-125a in the inhibition of docetaxel in the breast cancer proliferation. Methods: MCF-7 and MDA-MB-231 breast cancer cell lines and MDA-MB-231 breast cancer nude mice model with transferring miR-125a combined with docetaxel. The inhibition effect in the breast cancer proliferation was observed in the cell line and the nude mice model. Results: miR-125a has synergistic inhibition effect with docetaxel in proliferation of MDA-MB-231 and MCF-7 breast cancer cell lines, and the similar result was acquired in MDA-MB-231 breast cancer nude mice model. From this study, we also confirmed that MDA-MB-231 and MCF-7 breast cancer cell lines can be inhibited by transferring miR-125a alone. Conclusion: miR-125a has synergistic action with docetaxel in inhibiting the growth of breast cancer cell line and nude mice model, and miR-12Sa could be a potential target in breast cancer treatment.%背景与目的:研究表明miR-125a通过下调Her-2或者Her-3的表达抑制乳腺癌细胞生长,可能是指导乳腺癌治疗的靶点.本研究旨在观察miR-125a是否具有增强多西他赛对乳腺癌细胞株和裸鼠荷瘤模型的生长抑制作用.方法:转染miR-125a联合不同浓度多西他赛处理MCF-7和MDA-MB-231乳腺癌细胞株和MDA-MB-231乳腺癌裸鼠模型,观察细胞株和裸鼠接种肿瘤的生长情况.结果:miR-125a与多西他赛可协同抑制MDA-MB-231及MCF-7乳腺癌细胞株、MDA-MB-231乳腺癌裸鼠模型肿瘤的增殖,单纯转染miR-125a也可抑制MDA-MB-231及MCF-7乳腺癌细胞株的增殖.结论:miR-125a与多西他赛有协同抗乳腺癌作用,可成为乳腺癌靶向治疗的潜在靶点.